Further research is needed to gain a comprehensive understanding of the interplay between Mettl3 and KIAA1429 in the context of gastric cancer resistance.[31] In addition, it was found that apoptotic protease-activating factor 1 (APAF1)-binding lncRNA (ABL) was modified by Mettl3 m6A and recognized by insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1), which maintains ABL stability. Here, VIRMA is linked to gastric cancer.